Comments regarding Esmaeilzadeh Holding’s net asset value as of 30 June 2023
Esmaeilzadeh Holding AB (publ) (”EHAB”) today published its net asset value as of 30 June 2023. To provide further details on the changes compared to the previously published net asset value, EHAB is including comments below regarding two of the holdings in its portfolio.
As of 30 June 2023, EHAB’s fair value of its holding in Rebellion Capital AB (”Rebellion”) amounts to SEK 1,012.1 million (SEK 1,082.1 million as of 31 May 2023). The adjusted fair value is based on the valuation used in the implementation of a new incentive program in Rebellion during the second quarter of 2023.
As of 30 June 2023, EHAB’s fair value of its holding in Dentalum Group AB (“Dentalum”) amounts to SEK 542.0 million (SEK 630.5 million as of May 31, 2023), after EHAB’s investment of SEK 80.4 million in Dentalum’s share issue in June which was aimed towards its existing shareholders. The adjusted value of the holding has been determined through a comprehensive evaluation of various factors, including Dentalum’s development, valuations of comparable peers, the latest share issue predominantly to existing shareholders, growth prospects, and overall market conditions.
For more detailed information on other changes in EHAB's net asset value as of 30 June 2023, refer to EHAB's interim report for the first half of 2023, which will be published on July 28, 2023.
For further information, please contact:
Saeid Esmaeilzadeh, CEO and founder
Email: saeid@ehab.group
Nils Fredrik Lagerstrand, General Counsel & Deputy CEO
Phone: +46 720 90 26 99
Email: nilsfredrik@ehab.group
The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CEST on 17 July 2023.
About Esmaeilzadeh Holding AB (publ)
EHAB is an entrepreneurially driven investment company that invests in and develops resilient companies within selected industries. The primary focus is investments in operational groups with opportunities for both organic and acquisition-based growth. For more information, see www.ehab.group.